BUSINESS
    Lagevrio Joins NHI Price List, Normal Distribution to Start Once Ready
    August 19, 2022
    MSD’s COVID-19 pill Lagevrio (molnupiravir) was included in the Japanese NHI price list on August 18, opening the way for its distribution through normal channels, the company said. The drug maker did not disclose when…

    LATEST

    Astellas’ Hot Flash Med Accepted by FDA Review, Gets Short-Cut with Voucher Use
    August 19, 2022
    Astellas Pharma said on August 18 that the US FDA has accepted for review its nonhormonal agent fezolinetant for the treatment of vasomotor symptoms (VMS) associated with menopause, known as hot flashes or night sweats.The…
    Mochida to Roll Out Once-Daily Epadel on Sept. 12
    August 19, 2022
    Mochida Pharmaceutical said on August 18 that a new once-daily soft capsule version of its hyperlipidemia drug Epadel (ethyl icosapentate) listed the same day will be available on September 12.The new product, Epadel EM Capsules 2 g, is a self-emulsifying…
    Forxiga Replaces Januvia as Japan’s No. 1 Diabetes Drug in April-June: IQVIA
    August 18, 2022
    Forxiga (dapagliflozin) became the top-selling diabetes drug in Japan in April-June, according to data released by IQVIA on August 17. The SGLT2 inhibitor snapped the winning streak of the DPP-4 inhibitor Januvia (sitagliptin) for the…

    COLUMN

    Healthcare Collaboration between Governments and Biopharma: Key Success Factors for Life Science Manufacturers and Future Implications
    By Eric Persoff

    There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…

    COMMENTARY

    Govt Should Examine Challenges with Emergency Approval Scheme Exposed by Shionogi Pill Review
    By Izuru Ando

    Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…

    FY2022 Drug Maker Employment Survey

    Female Manager Ratio at Japan Drug Makers Finally Hits 10%, Foreign Peers Near 25%: Jiho Poll
    By Reiji Anasako

    The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…

    Jiho Survey: FY2022 Drug Price Revision

    Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally

    Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

    FY2022 Drug Pricing Reform

    MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts

    Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

    TRENDS

    15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally

    A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA